Kumar Rupesh, Dutta Anindita, Phukan Mayur Mausoom
Department of Biotechnology, The Assam Royal Global University, Guwahati, -781028, Assam, India.
Department of Medical Laboratory Technology, The Assam Royal Global University, Guwahati, 781035, Assam, India.
Immunol Res. 2025 Jan 16;73(1):35. doi: 10.1007/s12026-025-09592-y.
Toll-like receptors (TLRs) are crucial components of innate immunity. A specific form of genetic variation in TLR genes may increase the chance of developing leukemia. The present investigation conducted a comprehensive meta-analysis to examine the correlation between three TLR polymorphisms, namely TLR2 (rs3804099), TLR4 (rs4986790), and TLR9 (rs187084), within the leukemia risk group. An in-depth literature search was performed using Web of Science, PubMed, and Google Scholar to identify noteworthy research published in these scientific databases from 2012 to 2024. Research articles were evaluated according to rigorous inclusion criteria, and data was compiled for meta-analysis using Microsoft Excel (Ver. 2013), MedCalc (Ver. 19.3), and RevMan software (Ver. 5.3). Finally, 11 qualified studies were selected for the ongoing investigation, encompassing a combined total of 1315 leukemia cases and 1340 controls. Using a dominant genotype model, the meta-analysis found that the TLR2 (rs3804099) and TLR9 (rs187084) polymorphisms were strongly linked to higher risk of leukemia, with ORs of 2.042 (95% CI: 1.35-3.08, p = 0.001) and 1.38 (95% CI: 1.14-1.67, p = 0.001) respectively. Notably, the TLR4 (rs4986790) polymorphism did not exhibited any substantial correlation with the incidence of leukemia. The results indicate that variations in TLR2 and TLR9 genes could be considered a novel genetic biomarker for the leukemia development, highlighting their potential use in risk assessment and targeted therapies. This emphasizes the possibility of using these variations in evaluating risk and developing targeted remedies. However, greater research capacities are required to research into the fundamental mechanisms and authenticate these trends in other populations.
Toll样受体（TLRs）是先天免疫的关键组成部分。TLR基因中一种特定形式的基因变异可能会增加患白血病的几率。本研究进行了一项全面的荟萃分析，以检验白血病风险组中三种TLR多态性，即TLR2（rs3804099）、TLR4（rs4986790）和TLR9（rs187084）之间的相关性。使用Web of Science、PubMed和谷歌学术进行了深入的文献检索，以识别2012年至2024年在这些科学数据库中发表的值得关注的研究。根据严格的纳入标准对研究文章进行评估，并使用Microsoft Excel（2013版）、MedCalc（19.3版）和RevMan软件（5.3版）汇编数据进行荟萃分析。最后，选择了11项合格研究进行后续调查，总共包括1315例白血病病例和1340例对照。使用显性基因型模型，荟萃分析发现TLR2（rs3804099）和TLR9（rs187084）多态性与白血病风险升高密切相关，其比值比分别为2.042（95%置信区间：1.35 - 3.08，p = 0.001）和1.38（95%置信区间：1.14 - 1.67，p = 0.001）。值得注意的是，TLR4（rs4986790）多态性与白血病发病率没有任何显著相关性。结果表明，TLR2和TLR9基因的变异可被视为白血病发生的一种新型遗传生物标志物，突出了它们在风险评估和靶向治疗中的潜在用途。这强调了利用这些变异评估风险和开发靶向治疗方法的可能性。然而，需要更强的研究能力来研究其基本机制并在其他人群中验证这些趋势。
